Observers have called the mini-pump, which continuously delivers exenatide, a "game changer" because it has the potential to overcome medication adherence in the patients who are most resistant to treatment.
The new study in Diabetes Care comes more than a year after the initial results of the TECOS trial were presented at the American Diabetes Association Scientific Sessions.
This week, the top stories in managed care were that the Senate began the process of repealing the Affordable Care Act, Cigna and CVS moved away from the EpiPen, and the NCI Formulary will make it easier to study cancer drugs and their combinations.
Coverage of our peer-reviewed research in the healthcare and mainstream press.
The new definition applies to CGM devices that have FDA approval for dosing decisions. Right now, Dexcom's G5 meets the 5-part test.


April 12th, 2014
Hershey, PA
May 22nd to 25th , 2014
Fort Lauderdale, FL
August 14th to 16th, 2014
Stowe, VT
COPD Compendium
Diabetes Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium